1. Introduction {#sec1-jcm-08-01009}
===============

Osteoarthritis (OA) is considered to be one of the most disabling diseases in developed countries \[[@B1-jcm-08-01009]\], with pain being its most significant symptom, and it is often difficult to manage due to aggravation by weight-bearing and movement of the hip and knee joints. Medication including paracetamol, traditional nonsteroidal anti-inflammatory drugs (NSAIDs), and selective cyclooxygenase-2 inhibitors may be administered to relieve pain that originates from the joints; however, NSAIDs and selective cyclooxygenase-2 inhibitors also show many potentially serious side effects, especially in elderly patients \[[@B2-jcm-08-01009]\]. The 2008 and 2009 guidelines recommend the use of weak opioids or low doses of strong opioids when paracetamol, with or without topical NSAIDs, does not sufficiently relieve pain \[[@B2-jcm-08-01009],[@B3-jcm-08-01009]\]. However, although several randomized controlled studies have shown analgesic effects in musculoskeletal diseases, adverse effects are also commonly observed, and about 50% of patients discontinue opioid treatment due to these adverse effects \[[@B4-jcm-08-01009],[@B5-jcm-08-01009]\].

Concurrently, the intra-articular (IA) injection of opioids has been studied for some time ([Figure 1](#jcm-08-01009-f001){ref-type="fig"}). Opioid binding receptors have been identified within the synovium of joint spaces, suggesting that an analgesic effect from the opioid injected into the IA space may be locally mediated \[[@B6-jcm-08-01009]\]. When injected at the end of arthroscopic surgery, the IA opioid could reduce postoperative pain through peripheral opioid receptors \[[@B7-jcm-08-01009]\]. Furthermore, another opinion suggested that inflammation would destroy the perineurium of the nerve, and opioids would be better transported to opioid receptors due to the destroyed perineurium. It has also been reported to reduce pain through these pathways \[[@B8-jcm-08-01009]\], such as inflammatory reaction \[[@B9-jcm-08-01009],[@B10-jcm-08-01009],[@B11-jcm-08-01009]\].

Here, we suggest a novel method of application of a buprenorphine transdermal patch instead of the IA opioid injection, with the hypothesis that the application of this opioid transdermal patch on painful joints would transport the specific opioid component to joint spaces by diffusion ([Figure 1](#jcm-08-01009-f001){ref-type="fig"}). This hypothesis has subsequently been named Jong's hypothesis after Jong Bum Choi, the originator. In this study, we applied the buprenorphine transdermal patch to the painful knee joint of knee OA patients. The purpose of this research is to study the analgesic effects, adverse effects, and compliance of the buprenorphine transdermal patch applied to painful knee joints of knee OA patients, and to compare the knee applied group with the conventional chest applied group with respect to all parameters ([Figure 2](#jcm-08-01009-f002){ref-type="fig"}).

2. Materials and Methods {#sec2-jcm-08-01009}
========================

This study was a retrospective case-control study. Reviews of medical records were approved by the Institutional Review Board of the Ajou University Hospital of Korea (IRB No. AJIRB-MED-MDB-19-069), and registered at [ClinicalTrials.gov](ClinicalTrials.gov) (Identifier: NCT03947125) in May 2019. The requirement for informed consent was waived because of the retrospective case-control nature of the study.

2.1. Setting {#sec2dot1-jcm-08-01009}
------------

This research was performed in Ajou University School of Medicine in Suwon, Republic of Korea. The medical records were retrieved from January 2018 to December 2018. Recruitment and data collections were performed in April, 2019.

2.2. Participants {#sec2dot2-jcm-08-01009}
-----------------

Through medical records, we retrospectively enrolled 213 patients with OA of the knee who did not respond to conventional therapy. The inclusion criteria were as follows: (1) Age over 19 years; (2) diagnosis of OA of the knee by radiographic evidence of the aforementioned OA, as defined by Grades II to IV of the Kellgren and Lawrence scale \[[@B12-jcm-08-01009]\]; (3) pain score over 4 in the Numeric Rating Scale (NRS) from the relevant joint; and (4) buprenorphine transdermal patch prescribed for unilateral OA of the knee. The exclusion criteria were as follows: (1) History of total knee replacement surgery; (2) treatment with weak or strong opioid analgesics; (3) contraindications to treatments with opioid medication, such as a history of alcohol or substance abuse; (4) clinically significant systemic disease or any reduced organ function; (5) use of antidepressants, antiepileptic drugs, steroids, and/or hypnotics (that may have increased respiratory depression of buprenorphine) and; (6) missing data. Patients were divided into two groups, with the control group consisting of patients with a chest applied buprenorphine transdermal patch, and the other group consisting of patients with a painful knee joint applied with a knee applied buprenorphine transdermal ([Figure 3](#jcm-08-01009-f003){ref-type="fig"}). Buprenorphine transdermal patchs were replaced every seven days.

2.3. Clinical Evaluations {#sec2dot3-jcm-08-01009}
-------------------------

The NRS was checked before and at one month after the prescription of the buprenorphine transdermal patch. NRS before the buprenorphine patch was the average score across 1 week before the administration of the BTDP buprenorphine starts. NRS after buprenorphine patch was the average score during the administration of the buprenorphine patch. After buprenorphine patch was detached, NRS was not evaluated. The adverse effects of the buprenorphine transdermal patches were checked and recorded, while the compliance of the buprenorphine transdermal patch was also investigated. All parameters were then compared between the chest applied group and knee applied group.

2.4. Statistical Analysis {#sec2dot4-jcm-08-01009}
-------------------------

The sample size was 205 from a pilot study with a 15% drop out rate, which achieved 80.049% power, and a mean difference of −0.3, with a standard deviation of 0.3 for both groups, and with a significance level (alpha) of 0.050. The Student's t-test was used to compare the chest applied group and knee applied group in terms of the demographic data, while the Mann-Whitney U test, Chi-squared test, and the Fisher's exact tests were used to compare the two groups in terms of the NRS, adverse effects, compliance, and dose of buprenorphine administered. All data was analyzed both in intention to treat, and in per protocol. All statistical analyzes were performed using R software, version 3.5.1. A *p*-value less than 0.05 was considered to be statistically significant.

3. Results {#sec3-jcm-08-01009}
==========

The demographic data are shown in [Table 1](#jcm-08-01009-t001){ref-type="table"}. In intention to treat analysis, the NRS in the knee applied group after the buprenorphine transdermal patch application was lower than that of the chest applied group ([Table 2](#jcm-08-01009-t002){ref-type="table"}, [Figure 4](#jcm-08-01009-f004){ref-type="fig"}, *p* = 0.007). In per protocol analysis (except patients stopping buprenorphine transdermal patch), there were no differences between the chest applied group and the knee applied group ([Table 3](#jcm-08-01009-t003){ref-type="table"}). Furthermore, in the knee applied group, the total percentage of adverse effects was 19.32% (17/88, gastrointestinal (GI): 2, genitourinary: 1, and dermatological: 14) and in the chest applied group, it was 64.00% (80/125, gastrointestinal: 33, central nervous system (CNS): 24, skin problem: 15, and others: 8) ([Table 4](#jcm-08-01009-t004){ref-type="table"}, *p* \< 0.001). The compliance rates were 82.95% (73/88) and 37.60% (47/125) in the knee applied group and the chest applied group, respectively ([Table 2](#jcm-08-01009-t002){ref-type="table"}, *p* \< 0.001). The reasons for discontinuation were due to adverse effects, but a few patients with adverse effects continued to keep buprenorphine patch because of pain. The doses of buprenorphine of patient maintaining the patch were 6.71 ± 2.91 μg/h, and 7.66 ± 4.40 μg/h in the knee applied group and the chest applied group, respectively ([Table 5](#jcm-08-01009-t005){ref-type="table"}, *p* = 0.387), while the doses of buprenorphine in patients stopped were 7.00 ± 4.14 μg/h, and 6.99 ± 3.72 μg/h during the period when the BTDPs were applied in the knee applied group, and the chest applied group, respectively ([Table 5](#jcm-08-01009-t005){ref-type="table"}, *p* = 0.869). Effect size for the Mann-Whitney U test by R was 0.37 in comparison of NRS after buprenorphine patch.

4. Discussion {#sec4-jcm-08-01009}
=============

In this study, we found that our method of application of the buprenorphine transdermal patch directly to the painful knee joint of knee OA patients is more effective in reducing pain, and also less likely to have adverse effects compared with the conventional chest application method. Furthermore, the compliance was significantly higher in the knee applied group. These results allow for us to speculate that the absorption of buprenorphine might be greater at the local opioid receptors present in knee joints than when entering the systemic circulation.

In a previous study of 114 patients with chronic nonmalignant musculoskeletal pain, 50 patients (43.90%) stopped applying the buprenorphine transdermal patches due to the adverse effects observed, and subsequently dropped out. These adverse effects (78.10%) were generally mild or moderate, and mostly included nausea (39.50%) and constipation (31.60%), followed by dizziness (27.20%), somnolence (19.30%), vomiting (16.70%), headache (8.80%), pruritus (7.90%), and application site reactions (6.10%) \[[@B13-jcm-08-01009]\]. Similar results were observed in our study. In the chest applied group, adverse GI and CNS effects were observed in 33 cases (41.25%) and 24 cases (30.00%), respectively; in contrast, there were no CNS cases, and only two GI cases (11.76%) of adverse effects that had occurred in the knee applied group.

According to a review of previous studies of IA morphine injection after knee arthroscopy, the analgesic effect of morphine is mediated by local opioid receptors in the joint \[[@B7-jcm-08-01009]\]; here, its poor lipid solubility would hamper its passage across the synovial membrane into the bloodstream \[[@B14-jcm-08-01009]\]. The plasma morphine levels are much lower than what is generally accepted to be necessary for a systemic analgesic effect \[[@B15-jcm-08-01009],[@B16-jcm-08-01009],[@B17-jcm-08-01009]\]. Additionally, the partial agonist effect of buprenorphine at the µ-opioid receptor further reduces the adverse CNS and GI effects, along with having a ceiling effect for respiratory depression but not for analgesia, which results in a reduced risk for this potentially fatal adverse event as compared to other full opioid agonists \[[@B18-jcm-08-01009],[@B19-jcm-08-01009]\]. With respect to the adverse skin effects, the ratio of adverse skin effects to the total adverse effects was higher in the knee applied group, but the incidence was not much higher compared with the control group. This is due to the fact that when the patches are applied directly to a painful knee, the surface area of the skin that it can be attached to is limited. Nevertheless, the incidence of such adverse skin reactions was not significantly higher compared with the conventional method; therefore, patients may be recommended our new application method without major issues.

Two other pieces of research showed an effect size of 0.37 \[[@B20-jcm-08-01009],[@B21-jcm-08-01009]\]. The effect size of our results were 0.37, the same as the cut-off values shown in other research, therefore, a decision regarding the clinical relevance of the NRS scores could not be made.

Our findings need to be interpreted within the limitations of the study: (1) We could not analyze the concentration of buprenorphine directly by aspirating the joint fluid. Comparing the differences in concentrations between both groups would further support our hypothesis. (2) We could not analyze the differences in adverse effects due to dose differences. (3) This study is retrospective in nature, and has a relatively small sample size. For decreasing large placebo effects and verifying treatment effects, prospective randomized clinical trials with identically appearing placebo patches would be required in the future. (4) The effect size of this study were the same as the cut-off values from previous research, so a decision regarding its clinical relevance could not be made. This would need to be investigated in a further study. (5) This study did not exclude the effect of some medications (NSAIDs, acetaminophen and muscle relaxant, etc.) in participants.

5. Conclusions {#sec5-jcm-08-01009}
==============

In knee OA patients, the regional application of the buprenorphine transdermal patch directly to the painful knee joint showed an increase in effectiveness, compliance, and a decrease in adverse effects compared with the conventional chest application method.
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![(**a**) Intra-articular injection of opioids in the painful knee joint of knee osteoarthritis patients, (**b**) application of the buprenorphine transdermal patch on the painful knee joint of knee osteoarthritis patients (Jong's hypothesis).](jcm-08-01009-g001){#jcm-08-01009-f001}

![(**a**) Application of the buprenorphine transdermal patch on the chest of knee osteoarthritis patients (conventional application method), (**b**) application of the buprenorphine transdermal patch on the painful knee joint of knee osteoarthritis patients.](jcm-08-01009-g002){#jcm-08-01009-f002}

![A flow diagram of research. NRS, Numeric Rating Scale.](jcm-08-01009-g003){#jcm-08-01009-f003}

![Numeric rating scale (NRS) before buprenorphine transdermal patch application.](jcm-08-01009-g004){#jcm-08-01009-f004}

jcm-08-01009-t001_Table 1

###### 

Demographic data.

  ---------------------------------------------------------------------------------------------------
  **Variable**                   **Chest Applied Group**\   **Knee Applied Group**\   ***p*-Value**
                                 **(*n* = 125)**            **(*n* = 88)**            
  ------------------------------ -------------------------- ------------------------- ---------------
  Sex                                                                                 1.000 ^1^

  Male                           63 (50.40)                 44 (50.00)                

  Female                         62 (49.60)                 44 (50.00)                

  Age, years                     62.25 ± 15.44              57.00 ± 15.78             0.018 ^2,^\*

  Height, cm                     161.89 ± 9.46              164.15 ± 10.45            0.180 ^3^

  Weight, kg                     63.04 ± 13.18              64.82 ± 12.12             0.465 ^2^

  BMI, kg/m^2^                   23.86 ± 4.12               24.00 ± 3.39              0.826 ^3^

  KL grade ^4^                   II:59, III:61, IV:5        II:44, III:39, IV:5       0.892

  Malalignment (Varus, Valgus)   95 (76.00)                 69 (78.41)                0.681
  ---------------------------------------------------------------------------------------------------

Data are presented as *n* (%), Mean ± Standard Deviation for the numerical variables. ^1^ Chi-squared test was used. ^2^ Mann-Whitney test was used. ^3^ Student's t-test was used. \* *p* value \< 0.05. BMI: Body mass index. KL grade ^4^, Kellgren Lawrence grade.
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###### 

Comparison of the Numeric Rating Scale (NRS), adverse effects, and compliance between the chest applied group and knee applied group. (Intention to treat analysis).

  ---------------------------------------------------------------------------
  Variable          Chest Applied Group\   Knee Applied Group\   *p*-Value
                    (*n* = 125)            (*n* = 88)            
  ----------------- ---------------------- --------------------- ------------
  NRS before                                                     0.195

   buprenorphine                                                 

   application                                                   

   Mean ± SD        7.00 ± 0.31            7.06 ± 0.32           

  Median (Q1, Q3)   7 (7.00, 7.00)         7 (7.00, 7.00)        

  NRS after                                                      0.007 \*

   buprenorphine                                                 

   application                                                   

   Mean ± SD        4.79 ± 0.81            4.51 ± 0.69           

  Median (Q1, Q3)   5 (4.00, 5.00)         4 (4.00, 5.00)        

  Side effect                                                    \<0.001 \*

   No               45 (36.00)             71 (80.68)            

   Yes              80 (64.00)             17 (19.32)            

  Maintenance                                                    \<0.001 \*

   No               78 (62.40)             15 (17.05)            

   Yes              47 (37.60)             73 (82.95)            
  ---------------------------------------------------------------------------

Data are presented as *n* (%), Mean ± Standard Deviation for the numerical variables. Mann-Whitney U test was used for the numerical variables and Chi-squared test was used for the categorical variables. \* *p* value \< 0.05. NRS, Numeric Rating Scale.
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###### 

Comparison of the NRS, adverse effects, and compliance between the chest applied group and knee applied group (per protocol analysis).

  -------------------------------------------------------------------------
  Variable         Chest Applied Group\   Knee Applied Group\   *p*-Value
                   (*n* = 47)             (*n* = 73)            
  ---------------- ---------------------- --------------------- -----------
  NRS before\                                                   0.470
  buprenorphine\                                                
  application                                                   

  7.09 ± 0.35      7.04 ± 0.31                                  

  7 (7.00, 7.00)   7 (7.00, 7.00)                               

  NRS after\                                                    0.584
  buprenorphine\                                                
  application                                                   

  4.53 ± 0.75      4.45 ± 0.69                                  

  4 (4.00, 5.00)   4 (4.00, 5.00)                               

  Side effect                                                   0.644

  No               45 (95.74%)            71 (97.26%)           

  Yes              2 (4.26%)              2 (2.74%)             
  -------------------------------------------------------------------------

Data are presented as *n* (%), Mean ± Standard Deviation and Median (Q1, Q3) for the numerical variables. Mann-Whitney U test was used for the numerical variables and Fisher's exact test was used for the categorical variables. \* *p* value \< 0.05. NRS, Numeric Rating Scale.

jcm-08-01009-t004_Table 4

###### 

Comparison of the adverse effects between the chest applied group and knee applied group.

  ------------------------------------------------------------------------------------------
  Variables                          Chest Applied Group   Knee Applied Group   *p*-Value
  ---------------------------------- --------------------- -------------------- ------------
  Gastrointestinal system            33 (41.25)            2 (11.76)            

  nausea                             26                    1                    

  vomiting                           1                     0                    

  constipation                       4                     0                    

  dry mouth                          2                     1                    

  Central nervous system             24 (30.00)            0 (0.00)             

  dizziness                          18                    0                    

  somnolence                         6                     0                    

  Cardiovascular system              0 (0.00)              0 (0.00)             

  Genitourinary system\              0 (0.00)\             1 (5.88)\            
  urinary retention                  0                     1                    

  Respiratory system                 0 (0.00)              0 (0.00)             

  Skin and appendages\               15 (18.75)\           14 (82.35)\          
  dermatitis\                        6\                    4\                   
  irritation                         9                     10                   

  Special senses                     0 (0.00)              0 (0.00)             

  Body as a whole                    0 (0.00)              0 (0.00)             

  Metabolic and nutritional system   0 (0.00)              0 (0.00)             

  Others\                            8 (10.00)\            0 (0.00)\            
  general weakness                   8                     0                    

  Total                              80/125(64.00)         17/88(19.32)         \<0.001 \*
  ------------------------------------------------------------------------------------------

Data are presented as *n* (%). Fisher's exact test was used. \* *p* value \> 0.05.

jcm-08-01009-t005_Table 5

###### 

Comparison of the buprenorphine doses administered between the chest applied group and knee applied group.

  Variable                                  Chest Applied Group   Knee Applied Group   *p*-Value
  ----------------------------------------- --------------------- -------------------- -----------
  Buprenorphine dose of stopping group                                                 0.869
  *n*                                       78                    15                   
  Mean ± SD                                 6.99 ± 3.72           7.00 ± 4.14          
  Buprenorphine dose of maintenance group                                              0.387
  *n*                                       47                    73                   
  Mean ± SD                                 7.66 ± 4.40           6.71 ± 2.91          

Data are presented as Mean ± Standard Deviation. Mann-Whitney U test was used. SD, Standard Deviation.
